What Does Inversago Pharma Do?

Total employees9
HeadquartersMontréal
FoundedN/A

Inversago Pharma is a clinical-stage biopharmaceutical company, acquired by Novo Nordisk in 2023, focused on the discovery and development of next-generation, peripherally-acting CB1 receptor (CB1r) inverse agonists. These innovative therapies are designed to treat a range of metabolic disorders, including Prader-Willi syndrome (PWS), obesity, type 1 and type 2 diabetes, and diabetic nephropathy. By targeting the CB1r primarily outside the brain and spinal cord, Inversago aims to provide therapeutic benefits while minimizing centrally-mediated side effects. Their lead candidate, INV-202, is an oral CB1 inverse agonist being investigated for various metabolic conditions.

Where Is Inversago Pharma's Headquarters?

HQ Function

The headquarters serves as the primary center for Inversago's research and development activities, clinical program management, strategic planning, and administrative operations, now integrated within the Novo Nordisk framework.

Notable Features:

The facility likely includes specialized laboratory spaces for biopharmaceutical research, modern office areas designed for collaboration, and essential infrastructure to support ongoing clinical development programs. Specific architectural details are not broadly publicized but are functional for a research-driven biotech.

Work Culture:

The work culture at Inversago is rooted in scientific excellence, innovation, and a strong patient focus. It fosters collaboration and a commitment to developing impactful treatments for serious metabolic diseases, values that align with its parent company, Novo Nordisk.

HQ Significance:

Its Montréal location provides strategic access to a vibrant biotech ecosystem, including world-class academic institutions, a skilled talent pool, and a supportive network of research organizations, beneficial for its R&D objectives.

Values Reflected in HQ: The headquarters' setup aims to reflect Inversago's core values of scientific rigor, innovation in drug development, operational efficiency, and collaborative teamwork to advance medical science.

Location:

While its primary operations are based in Montréal, Canada, Inversago Pharma's clinical development activities for its drug candidates have a global scope, involving trial sites and collaborations in various countries. Since its acquisition by Novo Nordisk, Inversago's global reach and impact are significantly amplified through Novo Nordisk's extensive worldwide operational and commercial infrastructure, supporting the development and potential future distribution of its therapies.

Street Address:

750, boulevard Marcel-Laurin, Suite 485

City:

Montréal

State/Province:

Québec

Country:

Canada

Where Else Does Inversago Pharma Operate Around the World?

No additional office locations available.

Buying Intent Signals for Inversago Pharma

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Inversago Pharma? Meet the Executive Team

As of April 2025, Inversago Pharma' leadership includes:

François Ravenelle, PhD - Chief Executive Officer
Glenn D. Crater, MD, FACP - Chief Medical Officer
Caroline Fradette, PhD - Vice President, Preclinical Development
Philippe L’Allier, PhD - Vice President, Clinical Operations

Who's Investing in Inversago Pharma?

Inversago Pharma has been backed by several prominent investors over the years, including:

Forbion
New Enterprise Associates (NEA)
Sofinnova Partners
AdMare BioInnovations
Genesys Capital
AmorChem
Fonds de solidarité FTQ
Investissement Québec

What Leadership Changes Has Inversago Pharma Seen Recently?

Hire0
Exits1

The most significant executive-level event in the past 12-18 months was the acquisition by Novo Nordisk, which led to some leadership transitions. Notably, Martin D. LeBlanc, the former Chief Financial and Operating Officer, departed around the time of the acquisition in mid-2023. The core scientific and operational leadership, including CEO François Ravenelle, has largely remained to continue driving Inversago's pipeline within the new structure.

Departures

Martin D. LeBlanc, CPA, Departed as Chief Financial and Operating Officer following the acquisition by Novo Nordisk.

What Technology (Tech Stack) Is Used byInversago Pharma?

Discover the tools Inversago Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Inversago Pharma Email Formats and Examples

Inversago Pharma, like many companies in the biopharmaceutical sector, typically utilizes standardized email formats. The most common patterns observed or predicted for inversago.com are [first_initial][last]@inversago.com or [first].[last]@inversago.com.

[first_initial][last]@inversago.com

Format

fravenelle@inversago.com

Example

85%

Success rate

What's the Latest News About Inversago Pharma?

Endpoints News / Novo NordiskDecember 6, 2023

Inversago Pharma's acquisition by Novo Nordisk completed

Novo Nordisk announced the completion of its acquisition of Inversago Pharma. This move integrates Inversago's lead investigational drug INV-202 and its CB1 receptor technology into Novo Nordisk's pipeline, aiming to develop new treatments for obesity and metabolic diseases....more

Novo NordiskAugust 10, 2023

Novo Nordisk to acquire Inversago Pharma to develop new therapies for obesity, diabetes and complications associated with metabolic disease

Novo Nordisk entered into an agreement to acquire Inversago Pharma for a total consideration of up to 1.075 billion CAD. The acquisition is centered on Inversago's lead asset INV-202, an oral CB1 inverse agonist, with potential in treating metabolic disorders....more

Inversago Pharma / PR NewswireMay 2, 2023

Inversago Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of INV-202 for Prader-Willi Syndrome

Inversago Pharma announced the dosing of the first patient in its 'CARE' Phase 2 clinical trial for INV-202 in patients with Prader-Willi syndrome (PWS). The study aims to evaluate the efficacy, safety, and tolerability of INV-202, a peripherally-acting CB1 inverse agonist, in this rare genetic disorder characterized by metabolic disturbances....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Inversago Pharma, are just a search away.